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Introduction
Urinary tract infections are inflammatory diseases of 
infectious etiology, affecting 150  million people each year 
worldwide [1]. Currently in the Republic of Moldova there 
is an increased number of people suffering from infectious 
diseases of the urinary tract [2], which occur in any part of 
the urinary system: in kidneys, ureters, bladder and urethra, 
more frequently infections involve the lower urinary tract 
– the bladder and the urethra [3]. The risk factors for its 
developing include urinary obstruction, renal failure, renal 
transplantation, immunosuppression, diabetes, obesity, ge-
netic susceptibility, prolonged catheterization, sexual activ-
ity and older age. According to physicians the most common 
diseases are pyelonephritis, urolithiasis, glomerulonephritis 
and cystitis [4].
Most urinary tract infections are caused by Gram-
negative bacteria, namely Escherichia coli, Pseudomonas aeru-
ginosa, Klebsiella pneumoniae, Enterococcus faecalis, Proteus 
mirabilis, by Gram-positive bacteria as: Staphylococcus au-
reus, Staphylococcus saprophyticus and by yeast infections 
– Candida spp. For complicated urinary tract infections the 
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Abstract
Background: Urinary tract infections are the most common urogenital diseases, with an increased incidence in men and older people. Urogenital infections 
are caused by Gram-negative bacteria, in which Escherichia coli predominates with a share of 80%. The evolution of microbial resistance to preparations used 
in curative-prophylactic institutions, induces the need of the reintroduction of nitrofurans, noteworthy  for their wide spectrum of antibacterial activity.
Material and methods: For the study, suppositories with furazidine were prepared by hand rolling and by melting and molding methods. Quantitative 
analysis was performed spectrophotometrically on a UV-VIS Perkin Elmer Lambda 40 spectrophotometer. All solvents and reagents had the degree of 
purity ”pure for analysis” and ”chemically pure”.
Results: Duble cast method was applied to identify the exact mass of hydrophobic (cocoa butter, suppocire) and hydrophylic (polyethylene glycol mixtures) 
excipients. All the formulated suppositories were subjected to quality tests and showed acceptable physical characteristics and uniformity of drug contents. 
The UV-VIS spectrophotometric method for quantitiative determination of furazidine was developed and validated. The validation results showed that 
the developed method is simple, fast, accurate and robust.
Conclusions: Suppositories with furazidine were prepared by classic technological methods. Preparation of the suppositories with furazidine on cocoa 
butter excipient is a suitable alternative for individual medicinal prescriptions. The UV-VIS spectrophotometric dosing method for furazidine in 
suppositories was developed and validated.
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order of prevalence for causative agents is Enterococcus spp., 
K. pneumoniae, Candida spp., S. aureus and P. aeruginosa [3]. 
Depending on the severity of the disease, the treatment for 
each case is complex and is selected individually. 
Antibiotics are the most commonly recommended thera-
peutics however, increasing rates of antibiotic resistance and 
high recurrence rates threaten to greatly enhance the bur-
den that these common infections place on society. Today, 
nitrofuran antibiotics, despite the long-term use in medicine 
(since the 1950) is a class of synthetic substances that are 
revival and reintroduced as “old” antibacterials for treating 
multidrug-resistant pathogens [5, 6]. Nitrofurans have a 
wide spectrum of antimicrobial activity, which acts by dis-
rupting the process of cellular respiration of bacteria, inhibi-
tion the tricarboxylic acid cycle and causing disruption of 
nucleic acid synthesis and, ultimately, death of bacterial cells 
[7]. 
Furazidine (furazidinum) – is a nitrofuran derivative 
with properties analog to nitrofurantoin, used in the treat-
ment of urinary tract infections. It is an imidazolidine-2.4-
dione, an organonitrogen heterocyclic and an organooxygen 
heterocyclic antibiotic, derived from a  semicarbazide [8]. 
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Furazidine is a flavourless yellow or orange-yellow fine crys-
talline powder, bitter in taste. Very slightly soluble in water 
and ethanol, hardly soluble in dimethylformamide, slightly 
soluble in acetone, practically insoluble in chloroform and 
benzene. It is one of the most popular nitrofuran and is 
widely used in a large number of researches due to uses in 
medicine, in industrial and extemporaneous dosage forms 
and in cosmetology as well [9]. 
On Moldovan pharmaceutical market furazidine is pres-
ent in industrial commercial brand names of Furasol, Furagin 
and Furamag in dosage forms of powder, tablets and capsules 
[10]. The survey of the compounding dosage forms with fu-
razidine during the years of 2019-2021 in the production 
department of Vasile Procopisin University Pharmaceutical 
Center (UPhC), shows that the largest share is presented by 
semisolid pharmaceutical forms mostly in suppositories, fol-
lowed by solid pharmaceutical forms as powders. Specialists 
select the rectal route of administration of drugs because it 
avoids the first hepatic passage, does not allow irritation of 
the mucosa of the gastrointestinal tract, in case of intoleran-
ce to some active substances, demonstrates good absorpti-
on of drugs, rapid therapeutic action and mostly tolerable 
for pediatric and geriatric patients [11, 12]. Thus, based on 
the importance of the study, the semisolid medicinal forms 
– suppositories containing furazidine only or in combina-
tion with other active components, such as benzocaine, di-
mexide, methylene blue and other, are frequently prescribed 
in the treatment of urogenital diseases [13]. Pharmaceutical 
forms prepared in pharmacy, whether magistral prescripti-
ons prepared by the pharmacist on the basis of a medical 
prescription, or compounded dosage forms presented as 
stock elaborations prepared by the pharmacist on the basis 
of an official data from the pharmacopoeia, offer an effec-
tive alternative to industrial medicinal preparations. Vasile 
Procopisin UPhC of Nicolae Testemitanu SUMPh, is nowa-
days the leading compounding pharmacy from the Republic 
of Moldova and plays an important role in practic trainings 
of new generations of pharmacists concerning production, 
quality control and delivery of medicines [14]. 
The research was performed in order to develop the op-
timal composition of suppositories with furazidine prepared 
in the production department of Vasile Procopisin UPhC on 
hydrophilic and hydrophobic excipients using two prepara-
tion methods (hand rolling and molding), as well as to de-
velop and validate a spectrophotometric dosing method for 
furazidine in suppositories. The paper aimed to highlight the 
comparative analysis of technological methods of supposi-
tories prepared on water-soluble and fat-soluble excipients, 
quality control and quantitative determination according to 
the Analytical Standardization Documentation (ASD).
Material and methods
Reagents and chemicals. Furazidine – molecular for-
mula C10H8N4O5, produced by Chengdu HuaXia Chemical 
Reagent Co. Ltd, 99% purity. N,N-dimethylformamide and 
other reagents of analytical grade have been purchased from 
Sigma-Aldrich Chemie GmbH and Merck (Germany). All 
solvents had the degree of purity “pure for analysis” and 
”chemically pure”.
Preparation of suppositories. The preparation of the 
suppositories was performed in the Production Department 
of Vasile Procopisin UPhC. The elaboration of the composi-
tion and preparation of the suppositories on water-soluble 
excipients: PEG 400: 4000 (1:9); PEG 400: 1500 (0.5:9.5); PEG 
400: 1500: 4000 (1:3:6), as well as on fat-soluble excipients: 
cocoa butter and suppocire was performed in accordance 
with the requirements of the European Pharmacopoeia [15]. 
Double cast technique. The amount of substance for a 
suppository was mixed with a part of the molten excipient 
and poured into the suppository mold. Calculations were 
made for 10 suppositories. Then the excess molten excipi-
ent was poured into each cavity, cooled and the excipient 
left outside the level of the mold cavities was scraped and 
removed. At the beginning, 10 suppositories obtained from 
the clean excipient were weighed, then 10 suppositories con-
taining the excipient and each substance were weighed and 
the average mass was calculated for each. 
Evaluation of suppositories. Visual characterization 
– twenty suppositories from each batch were randomly se-
lected, longitudinally cut and examined through naked eyes 
for the assessment of physical characters. Weight variation – 
twenty suppositories were weighed and average weight was 
calculated. Each suppository was weighed individually on 
electronic balance (WLC 6/12 precision electronic pharma-
ceutical balance). No suppositories should deviate from av-
erage weight more than 7.5%. Melting point – melting range 
test was performed with the whole suppository. Suppository 
from each formulation was placed in a test tube with phos-
phate buffer pH 7.2 maintained at constant temperature 37± 
0.5°C. The time required for the whole suppository to melt 
or disperse in the media was noted. Penetration test – this 
test was used to determine the temperature at which the 
suppository becomes sufficiently soft for a penetrating rod 
to drop through its length. Test apparatus Erweka PM 30, 
phosphate buffer pH 7.2 maintained at 37±0.5°C was used 
for this testing, the time taken for the penetration of entire 
suppository was recorded. 
Drug content – was determined spectrophotometrically 
on Perkin Elmer Lambda 40 UV/VIS spectrophotometer, 
using solvents and reagents with a degree of purity ”pure for 
analysis” and ”chemically pure”, various laboratory and phar-
maceutical utensils. 
In-vitro dissolution study. The study was carried out 
using dissolution apparatus USP Type II (Paddle) with ap-
paratus Erweka DT6, dissolution medium – phosphate buf-
fer, pH 7.2, the speed of paddle – 100 rpm, temperature of 
medium – 37 ± 0.5°C.
Validation of the UV-spectrophotometric method. The 
analytical parameters of linearity, accuracy, selectivity and 
robustness were evaluated for validation of the spectropho-
tometric method.
Statistical analysis. All measurements were carried out 
in triplicate and expressed as mean (n=3) ± standard devia-
tion (n=3) of three replicates. Construction of curves and 
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graphical presentation were performed by MS Office Excel 
2016, as well as identifying the differences between values. A 
probability value of p≤0.05 was considered to be significant.
Results and discussion
Preparation of suppositories. The active substance fura-
zidine – a compound from the group of nitrofurans, with an-
timicrobial effect against specific microorganisms [16, 17], 
was used for the study. Due to the unwanted reactions that 
furazidine can manifest in the oral administration of medi-
cinal preparations, suppositories are an effective and advan-
tageous alternative. Furazidine – IUPAC name 1-[3-(5-ni-
trofuran-2-yl)prop-2-enylideneamino]imidazolidine-2.4-
dione, has a pKa value of 8.23, characteristic for a substance 
with weak acidic properties. Calculating the percentage of 
non-ionized form [11] at the rectal average pH of 7.9 we can 
conclude that furazidine is satisfactorily absorbed at a neu-
tral to slight basic pH, reported in adults [12].
Furazidine suppositories were prepared on a hydrop-
hobic excipient of cocoa butter, by the method of manual 
modeling [18]. Subsequently the composition was develo-
ped for suppositories obtained by the melting and casting 
method prepared on suppocire and with polyethylene gly-
cols (PEGs): PEG 400: 4000 (1:9); PEG 400: 1500 (0.5:9.5); 
PEG 400: 1500: 4000 (1:3:6). In order to efficiently and qua-
litatively achieve the method of preparing suppositories by 
melting and casting in patterns, the calculation of the dis-
placement factors for each component of each assortment 
of suppositories with application of Double Casting Method 
was performed [13]. It is necessary to know the capacity of 
the forms and the value of the displacement factor, respecti-
vely the amount of displaced excipient of 1.0 g of active sub-
stance, mechanically dispersed in the excipient, according to 
the formula (1):
f = ρ excipient / ρ active substance, (1) 
where:  f – displacement factor; ρ – density.
To compensate for the losses, an excess will be taken, de-
pending on the number of suppositories to be prepared. The 
results obtained were used to calculate the mass of the ex-
cipients. The stages of the technological process of prepara-
tion of suppositories by the method of melting and casting in 
molds, were applied to hydrophobic base suppocire and for 
water-soluble excipients based on PEGs. The method con-
sisted of pouring the mixture of active substances and excip-
ient, hot fluidized, in forms corresponding to the subsequent 
cooling of suppositories. The stages of the technological flow 
of preparation of suppositories by the method of melting and 
molding in patterns are shown in fig. 1.
The preparation process depends on the properties of 
the active substances, so the furazidine was incorporated by 
suspension, in micronized form with dimensions between 
50-100 µm. In the method of melting and casting into molds, 
melting of the excipient and mixing with the active substanc-
es is done in containers heated with water vapor, at a con-
trolled temperature to avoid overheating [19]. Great atten-
tion has been paid to the homogeneity of the mixture when 
molding to avoid the tendency of sedimentation, therefore 
the mixture must be less fluid, stirring continuously during 
casting for a correct dosage. Drug has been suspended with 
the adjustable speed pistil, to ensure perfect homogenization 
in the mixture, with convenient viscosity, to maintain a ho-
mogeneous suspension of the incorporated active substance. 
Uniform flow in the molds was ensured.
The hand rolling method was applied for fat-soluble ex-
cipient cocoa butter. Suppositories were obtained by manual 
method, initially in the mortar furazidine was crushed in the 
presence of peach oil [20], the mixture was homogenized 
with cocoa butter until obtaining the appropriate consisten-
cy. Subsequently, the suppository mass was divided into ap-
propriate doses, from which rectal suppositories were mod-
eled, packaged in parchment paper, then in plastic boxes. 
The preparation was shaped, labeled according to the provi-
sions of the ASD. The scheme of the technological process of 
preparation of suppositories by the method of hand rolling 




by suspension and 
emulsification in the 
excipient base
Mixing and kneading 
the mixture until the 
suppository mass 
is obtained at room 
temperature
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Packing in plastic 
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Fig. 2. the stages of the technological flow of obtaining 
suppositories by hand rolling method 
Evaluation of suppositories. Twenty suppositories from 
each batch were randomly selected, longitudinally cut and 
examined through naked eyes for the assessment of physi-
cal characters like absence of fissuring, pitting, fat blooming, 
exudation and migration of active ingredients. Suppositories 
have a homogeneous appearance, yellowish in color, which 
retains its shape and consistency at room temperature. 
Weight variation: twenty suppositories were weighed and 
average weight was calculated. Each suppository was weighed 
individually on WLC 6/12 electronic balance. No supposito-
ries deviated from average weight by more than 5%, accord-
ingly meeting the pharmacopoeia requirement [21].
Melting point: Macro melting range test was performed 
with the whole suppository. Suppository from each formu-
lation was placed in a test tube with phosphate buffer pH 
Fig. 1. Scheme of the technological flow of preparation of 
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7.2 maintained at constant temperature 37± 0.5°C. The time 
required by the whole suppository to melt or disperse in the 
media was noted. The melting time plays a crucial role in the 
release of active ingredient. 
Penetration test: the study was carried out using appara-
tus Erweka PM 30, in medium of distilled water at tempera-
ture of 37±0.5°C. The average results are presented in table 1.
Quantitative determination of furazidine in supposito-
ries was carried out by UV-VIS spectrophotometric meth-
od. Several solvents were selected for the elaboration of the 
technique for the extraction of medicinal substances from 
suppositories containing furazidine: purified water, dimeth-
ylformamide solution, acetate buffer and 96% ethyl alcohol. 
Repeated extraction with dimethylformamide met all the 
requirements for qualitative and quantitative analysis of fu-
razidine, the extraction yield being 94%. 
Extraction technique – 1 suppository (mass 3.0 g) was 
brought into a 100 ml beaker, 60 ml of dimethiformamide 
was added and mixed vigorously for 20 minutes. 30 ml of 
96% ethyl alcohol was added, stirred, added 96% alcohol 
to the quota and mixed. The obtained mixture was filtered 
through filter paper; the first portions were discarded. 0.25 
ml of the filtrate was placed in a volumetric flask and mixed 
with acetate buffer to the level.
The UV-VIS spectra of the 5 μg/ml furazidine samples 
recorded in the 230-450 nm region showed a maximum ab-
sorption for the standard furazidine solution at 292 nm, for 
the suppositories prepared on cocoa butter and suppocire 
at 286.11 nm, and for the suppositories with furazidine pre-
pared on PEGs, the absorption spectrum at the wavelength 
of 286.04 nm was recorded, using the Perkin Elmer Lambda 
40 UV/VIS spectrophotometer (fig. 3). 




X - Furazidine content in the sample, g; 
A₁ - Wavelength of the solution to be analyzed; 
Ao - Wavelength of the standard furazidine solution; 
ao - mass of furazidine standard, g; 
C – Amount of active substance, %. 
The results for all assortments of suppositories meet the 
pharmacopeial requirements and are presented in table 1. 
All the suppositories prepared with furazidine showed ac-
ceptable physical characteristics and uniformity of drug con-
tents. 
The in-vitro drug release profile from different supposi-
tories formulation is shown in fig. 4. The dissolution study 
showed that the suppositories melted in the dissolution me-
dium maintained at 37±50C. All five formulations showed 
more than 50% drug release within 60 minutes.
Fig. 4. Dissolution profiles of suppositories with furazidine using 
different types of excipients
In cocoa butter suppositories, the drug release was sli-
ghtly slower due to high lipophilicity of the base and non-
 











Cocoa butter q.s. ad 3.0 g
3.2±0.032 31.2±1.2°C 15.4±0.81 98.9% ±0.04
Furazidine 0.1 g
Suppocire q.s. ad 3.0 g
3.0±0.032 36.8±0.12°C 17.25±0.73 97.14% ±0.83
Furazidine 0.1 g
PEG 400: 4000 (1:9) q.s. ad 3.0 g
3.07±0.014 34.7±0.52°C 22.3±0.64 98.55%±0.112
Furazidine 0.1 g
PEG 400:1500:4000 (1:3:6) q.s. ad 3.0 g
3.05±0.07 36.17±0.52°C 19.4±0.95 98.72±1.37
Furazidine 0.1 g
PEG 400:1500 (0.5:9.5) q.s. ad 3.0 g
3.01±0.001 37.6±0.1°C 59.5±0.77 94.5±0.02
Note: *Average mass of 20 suppositories; **Average of 3 measurements; ± Standard Deviation.
Fig. 3. UV spectrum of furazidine in evaluated formulations
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miscibility of the base with the dissolution media, charac-
teristic for hydrophobic bases [22]. Furthermore, the lack 
of surfactants might have acted as a significant variable in 
the fat-based formulation in the release of furazidine [23, 
24]. Suppositories prepared with the combination of PEG 
400:1500:4000 (1:3:6) showed the maximum furazidine re-
lease (92.4%) within 60 minutes.
Validation of the UV-VIS dosing spectrophotometric 
method. UV-VIS spectrophotometric methods [25] for do-
sing furazidine in suppositories were developed and valida-
ted. Validation parameters were calculated according to SR 
ISO 8466 / 1-2016 European Pharmacopoeia Standard, Ed. 
9.0 (2020) and ICH-Q2B-Validation of Analytical Procedu-
re: Methodology (2005). The statistical parameters that were 
used to validate the method were: linearity, repeatability, ac-
curacy and robustness. The first step was to select the solvent 
for the extraction of the active substances. Extraction tech-
nique used: a suppository (mass of 3.0 grams) was brought 
into a 100 ml beaker, 60 ml of dimethiformamide was added 
and mixed vigorously for 20 minutes, futher mixed with 30 
ml of 96% alcohol and brought with 96% alcohol to the quo-
ta. The mixture obtained was filtered through filter paper, 
the first portions were discarded, and 0.25 ml of the filtrate 
was brought into a volumetric flask and mixed with acetate 
buffer up to 100 ml.
Preparation of the standard solution. 0.05 g (exact mass) 
preventively dried furazidine at a temperature of 100-105˚C, 
until the exact mass, is dissolved in 60 ml of dimethiforma-
mide in a 100 ml volumetric flask, 30 ml of 96% ethyl alcohol 
are added, and mixed well.1 ml of solution was brought to a 
100 ml volumetric flask, mixed with the acetate buffer to the 
level. The solutions were used ready-made.
The selectivity of the dosing method was determined by 
analysis of a control sample. At the wavelength of 292 nm 
corresponding to the furazidine determination, the control 
sample led to an absorbance value of 0.001. The accuracy 
of the developed methods was determined at 3 concentra-
tion levels: 80%, 100% and 120% by the standard addition 
method. The furazidine concentration was calculated using 
the linear regression equations established at the linearity 
parameter. The equation of linear regression for furazidine 
dosing was: y = 0.238x + 0.014, R2 – 0.999. 
The degree of accuracy, repeatability and intermediate 
accuracy was investigated. Repeatability was determined for 
4 samples, at the concentration level of the drug substances 
of 100%, on the same day, respecting the same conditions. 
The degree of accuracy was investigated in 2 different days, 
under the same conditions, performing 5 determinations for 
each assortment of suppositories. Changes in the wavelength 
of absorption were performed to evaluate the robustness of 
the method. During the analysis of the pharmaceutical prod-
ucts, the levels found no significant difference and the rela-
tive standard deviation was below 0.93%, demonstrating the 
robustness of the proposed method, thus, furazidine in sup-
positories can be detected in low concentrations (tab. 2).
The UV-VIS spectrophotometric method for quantitia-
tive determination of furazidine in evalueated suppositories 
was developed and validated. The validation results show 
that the developed method is simple, fast, accurate and ro-
bust.
Conclusions
In this paper, suppositories with furazidine were formed 
by hand rolling and molding methods and were subjected 
to physical evaluation, weight variation, content uniformity, 
melting point, penetration time test and in-vitro dissolution 
studies. All tests showed satisfactory results. 
All five formulations showed more than 50% drug release 
within 60 minutes. Based on the in-vitro release rate studies, 
it can be concluded that PEG 400:1500:4000 can be used as 
a base which is easily soluble in aqueous medium, disperses 
rapidly and has higher rate of release for immediate release 
of furazidine and is recommended for bulk pharmaceutical 
elaborations. 
Preparation of the suppositories with furazidine on co-
coa butter excipient is a suitable alternative for individual 
medicinal prescriptions.
The UV-VIS spectrophotometric dosing method was de-
veloped and validated, this method could be included in the 
analytical procedures and documentations in the perspec-
tive of the quality evaluation of furazidine suppositories, the 
obtained results will serve as landmark for real-time stability 
studies.
table 2.  Results of validation of UV-VIS spectrophotometric dosing method  
for furazidine from suppositories
Validation parameters
Suppositories with furazidine on 
hydrophobic base
Suppositories with furazidine on 
hydrophylic base
Repeatability
Substance content, g 0.108 0.989
Coefficient of variation,% 0.550 0.467
Precision, day 1
Substance content, g 0.106 0.160
Coefficient of variation,% 0.618 0.645
Precision, day 2
Substance content, g 0.107 0.108
Coefficient of variation,% 0.589 0.542
Robustness Coefficient of variation,% 286.04 nm: 0.005 286.11nm: 0.006
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